Despite Labcorp Holdings’ underperformance relative to its industry peers, Wall Street analysts remain strongly optimistic ...

Labcorp Holdings recently reported better-than-expected Q3 2025 adjusted EPS of $4.18 but cut its contract research unit’s annual and full-year revenue growth forecasts due to a prolonged funding ...

Labcorp's strategic partnerships, specialty test growth and more attractive valuation tilt the balance as it emerges stronger than Hologic right now.

Labcorp Holdings ( ($LH) ) has provided an update. On December 10, 2025, Labcorp Holdings announced the retirement of Dr. D. Gary Gilliland from ...

A St. Louis biotech company has secured new funding from a major lab services business and a health system venture capital ...

Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.

Detailed price information for Laboratory Corp of America Holdings (LH-N) from The Globe and Mail including charting and trades.

St. Louis-based Ascension Ventures and Labcorp have invested in a strategic financing round for Cofactor Genomics. The company’s flagship test, OncoPrism, uses machine learning to analyze tumors and ...

The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and ...

Onconetix ( ($ONCO) ) has shared an announcement. On December 6, 2025, Proteomedix AG, a subsidiary of Onconetix, Inc., amended its license ...